Gain Therapeutics (GANX) Enterprise Value (2020 - 2025)
Gain Therapeutics has reported Enterprise Value over the past 6 years, most recently at -$8.8 million for Q3 2025.
- Quarterly results put Enterprise Value at -$8.8 million for Q3 2025, up 26.91% from a year ago — trailing twelve months through Sep 2025 was -$8.8 million (up 26.91% YoY), and the annual figure for FY2024 was -$10.4 million, up 38.16%.
- Enterprise Value for Q3 2025 was -$8.8 million at Gain Therapeutics, down from -$6.7 million in the prior quarter.
- Over the last five years, Enterprise Value for GANX hit a ceiling of -$6.7 million in Q2 2025 and a floor of -$46.6 million in Q1 2021.
- Median Enterprise Value over the past 5 years was -$16.9 million (2024), compared with a mean of -$21.5 million.
- Biggest five-year swings in Enterprise Value: plummeted 391.46% in 2021 and later surged 60.39% in 2025.
- Gain Therapeutics' Enterprise Value stood at -$36.9 million in 2021, then skyrocketed by 45.4% to -$20.1 million in 2022, then increased by 16.6% to -$16.8 million in 2023, then soared by 38.16% to -$10.4 million in 2024, then increased by 15.2% to -$8.8 million in 2025.
- The last three reported values for Enterprise Value were -$8.8 million (Q3 2025), -$6.7 million (Q2 2025), and -$9.1 million (Q1 2025) per Business Quant data.